Gattex Approval History

  • FDA approved: Yes (First approved December 21st, 2012)
  • Brand name: Gattex
  • Generic name: teduglutide
  • Company: NPS Pharmaceuticals, Inc.
  • Treatment for: Short Bowel Syndrome

Gattex (teduglutide) is a recombinant analog of human glucagon-like peptide 2 for the treatment of adults with short bowel syndrome.

FDA Approval History for Gattex

DateArticle
Dec 21, 2012Approval FDA Approves Gattex to Treat Short Bowel Syndrome
Oct 16, 2012FDA Advisory Committee Unanimously Recommends Approval of Gattex (teduglutide) for Adults with Short Bowel Syndrome (SBS)
Oct 12, 2012FDA Posts Briefing Documents for Advisory Committee Meeting Reviewing Gattex (teduglutide) for Adult Short Bowel Syndrome
Aug 21, 2012NPS Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Gattex (teduglutide)
Aug 13, 2012NPS Pharmaceuticals Announces Extension of Action Date for Gattex NDA to December 30, 2012
Jan 31, 2012NPS Pharmaceuticals Announces FDA Acceptance of New Drug Application for Gattex (teduglutide) for the Treatment of Adult Short Bowel Syndrome (SBS)
Dec  1, 2011NPS Pharmaceuticals Completes Submission of New Drug Application for Gattex (teduglutide) in Adult Short Bowel Syndrome (SBS)
Aug 18, 2011NPS Pharmaceuticals Submits Chemistry, Manufacturing and Controls (CMC) Section of New Drug Application for Gattex

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web3)